Oxiracetam

Summary

Oxiracetam (CHEMBL36633) is a phase-3 clinical-stage small molecule (ATC N06BX07); indicated across 1 condition including attention deficit-hyperactivity disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N06BX07
• Indications: 1 condition
• Chemistry: 158.16 Da · C6H10N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL36633
Name	Oxiracetam
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	4626
ATC	N06BX07
Molecular formula	C6H10N2O3
Molecular weight	158.16
InChIKey	IHLAQQPQKRMGSS-UHFFFAOYSA-N

SMILES: C1C(CN(C1=O)CC(=O)N)O

IUPAC name: 2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide

Also known as: CGP 21690E, CGP-21690E, GNF-PF-1005, Oxiracetam, GNF-Pf-1005, SID50106803, SID90341150, SID85231168, OXIRACETAM, oxiracetam, OxiracetamÊ, OxiracetamÂ

Patent coverage: 1,390 distinct patent families (3,366 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: RecQ-like DNA helicase BLM, DNA repair nuclease/redox regulator APEX1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).